EMA Authorised: Loqtorzi (toripalimab) — Topalliance Biosciences Europe Limited

View source ↗

Summary

EMA authorised Loqtorzi (toripalimab) for nasopharyngeal carcinoma and esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Nasopharyngeal Carcinoma

Drugs mentioned

• LOQTORZI (TORIPALIMAB-TPZI)

Snippet

Status: Authorised. Therapeutic area: Nasopharyngeal Carcinoma;Esophageal Squamous Cell Carcinoma. MAH: Topalliance Biosciences Europe Limited. Decision date: 31/07/2026